; and (2) relevant stakeholders, including drug manufacturers, health care providers, medical professional societies, State-based societies, public health experts, State and local public health departments, State medical boards, patient groups, health care distributors, wholesalers and group purchasing organizations, pharmacists, and other entities with experience in health care and public health, as appropriate. (c) Definitions For the purposes of this section: (1) The term critical drug means a drug that is described in subsection (a) of section 506C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c ) (relating to notification of any discontinuance or interruption in the production of life-saving drugs). (2) The term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ).